A “major step” toward a possible cure for HIV with a technique that targets the virus as it lays dormant in people receiving treatment thus escaping being attacked by current therapy.
Read More
Pinnacle Hill, the drug spinout company formed in partnership with UNC and Deerfield Management, recently said it would support a project led by Lindsey Ingerman James, Ph.D., a UNC Eshelman School of Pharmacy chemical biology and medicinal chemistry division assistant professor.
Read More
The platform will be called FABRIC, and it will provide a “nationwide testbed” for reimagining how data can be stored, computed and moved through shared infrastructure.
Read More
Thanks a $5 million injection from the John S. and James L. Knight Foundation, a new research center at UNC Chapel Hill is looking to answer “defining questions” about the changing nature of society and politics in this digital age.
Read More
Only one in eight Americans is achieving optimal metabolic health. This carries serious implications for public health since poor metabolic health leaves people more vulnerable to developing serious health issues.
Read More
Durham-based GeneCentric Therapeutics Inc. announced Monday that it has acquired a license to technology that could help fight pancreatic cancer.
Read More
Early, partial results from a historic gene editing study give encouraging signs that the treatment may be safe and having at least some of its hoped-for effect, but it’s too soon to know whether it ultimately will succeed.
Read More
Companies vying for talent offer an unusual array of benefits like college loan repayment, egg freezing, surrogacy assistance and, for new mothers away on business trips, overnight breast milk shipping. Some companies have added genetic screening. Is that a good idea? A UNC professor has doubts.
Read More
Clinical data company TARGET PharmaSolutions of Chapel Hill has added to its stable of major pharmaceutical company strategic alliances by adding Novartis to its study of liver disease.
Read More
